
Sign up to save your podcasts
Or


We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.
By Retina Synthesis4.5
88 ratings
We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.

43 Listeners

18 Listeners

100 Listeners

113,121 Listeners

56,944 Listeners

5 Listeners

9,556 Listeners

11 Listeners

47,718 Listeners

51 Listeners

11 Listeners

470 Listeners

19 Listeners

0 Listeners